European Approval for Catumaxomab: A Major Step for Malignant Ascites Treatment

Lindis Biotech GmbH, in collaboration with Pharmanovia, announced the European Commission's marketing authorisation for catumaxomab. This approval makes catumaxomab the sole approved drug for malignant ascites, a severe complication of advanced-stage cancer affecting numerous patients across Europe.

Under a new licensing agreement, Lindis Biotech has entrusted Pharmanovia with the exclusive rights to market and distribute catumaxomab throughout Europe. This strategic move underscores Pharmanovia's expanding influence in the specialty pharmaceutical sector.

Catumaxomab targets epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, addressing patients not eligible for other therapies. By engaging the body's immune system, it represents a novel approach to improving the quality of life for those afflicted by malignant ascites.